Valneva (NASDAQ:VALN) Shares Gap Up – Here’s Why

Valneva SE Sponsored ADR (NASDAQ:VALN)’s share price gapped up prior to trading on Tuesday . The stock had previously closed at $5.30, but opened at $5.74. Valneva shares last traded at $5.6950, with a volume of 12,095 shares traded.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. Wall Street Zen upgraded Valneva from a “strong sell” rating to a “sell” rating in a research report on Monday, June 1st. The Goldman Sachs Group cut Valneva from a “neutral” rating to a “sell” rating and set a $4.90 price objective on the stock. in a report on Wednesday, April 22nd. Guggenheim set a $11.00 target price on Valneva in a research note on Thursday, April 16th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Valneva in a report on Thursday, June 18th. Finally, TD Cowen began coverage on Valneva in a research report on Tuesday. They set a “buy” rating and a $12.00 price target on the stock. Four research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $11.98.

Valneva Stock Performance

The firm has a market capitalization of $545.14 million, a PE ratio of -3.07 and a beta of 1.77. The company has a quick ratio of 1.60, a current ratio of 2.14 and a debt-to-equity ratio of 2.14. The company has a 50-day moving average of $5.21 and a 200 day moving average of $7.01.

Valneva (NASDAQ:VALN) last released its quarterly earnings results on Tuesday, March 31st. The company reported ($0.42) earnings per share for the quarter. The business had revenue of $35.77 million during the quarter. Valneva had a negative net margin of 88.87% and a negative return on equity of 107.63%. Equities research analysts predict that Valneva SE Sponsored ADR will post -1 EPS for the current year.

Institutional Investors Weigh In On Valneva

A number of institutional investors and hedge funds have recently bought and sold shares of VALN. China Universal Asset Management Co. Ltd. bought a new stake in Valneva during the fourth quarter valued at approximately $44,000. Marex Group plc purchased a new stake in shares of Valneva during the 2nd quarter valued at $64,000. XTX Topco Ltd bought a new stake in shares of Valneva during the 4th quarter worth $94,000. Finally, JPMorgan Chase & Co. bought a new stake in shares of Valneva during the 3rd quarter worth $124,000. 11.39% of the stock is owned by hedge funds and other institutional investors.

About Valneva

Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. Headquartered in Saint-Herblain, France, the company applies inactivated whole-cell and recombinant technology platforms to address public health needs. Valneva’s research and development efforts span a range of viral and bacterial pathogens, with an emphasis on travel-related and emerging infectious diseases.

Among its marketed products, Valneva offers IXIARO®/JESPECT® for the prevention of Japanese encephalitis and DUKORAL® for the prevention of cholera and diarrhea caused by enterotoxigenic Escherichia coli.